Tag:
Qiagen
Latest Headlines
Latest Headlines
Roche gains FDA sign-off on lung cancer companion Dx
Roche's surging diagnostics arm scored a major win this week, gaining FDA approval what is being billed as the first companion diagnostic meant to detect a specific mutation connected to metastatic non-small cell lung cancer.
Qiagen plucks Ingenuity Systems from genomics analysis pack in $105M buyout
Qiagen has purchased Ingenuity Systems for $105 million in cash. The Netherlands-based buyer plans to integrate the genomic database and analysis software from Ingenuity into its molecular diagnostics business. The buyout highlights the growing value of understanding the nuances of genomics to make precise diagnoses.
Qiagen buys Ingenuity Systems for $105M
Dutch diagnostics giant Qiagen grabbed Ingenuity Systems in a $105 million cash deal, giving it new technology to boost the analysis of genomic data for molecular diagnostics.
Lilly cozies up to Qiagen for more companion diagnostics
Eli Lilly is expanding its partnership with Qiagen, building off of past success in a new broad collaboration agreement for companion diagnostics.
Qiagen seeks FDA sign-off for lung cancer companion Dx
Qiagen disclosed it is seeking the FDA's blessing for a lung cancer-drug companion diagnostic, a test designed to screen patients for whom Boehringer Ingelheim's investigational treatment might work.
Qiagen swings to 17% income drop despite revenue jump
Diagnostics outfit Qiagen ticked its revenue up 5.3% in the third quarter, but acquisition gains from last year made for a 17% decline in net income in the period.
Qiagen inks companion Dx deal with Bayer
Qiagen has signed on with Bayer to develop companion diagnostics for Bayer's solid tumor treatments, using the company's QIAsymphony Dx platform.
FT: Erbitux nod marks sea change in companion Dx
Last month's FDA approval of Qiagen's diagnostic for the cancer drug Erbitux is indicatative of a trend in pharma: Drugmakers and regulators are recognizing the importance of companion diagnostics in the world of targeted treatments, The Financial Times reports.
FDA approves Erbitux test for launch by BMS, Eli Lilly
The FDA has approved Qiagen's genetic biomarker-based therascreen KRAS RGQ PCR Kit. This can pick out the metastatic colon cancer patients who are most likely to respond to Erbitux (cetuximab), and this test will be launched by Bristol-Myers Squibb and Eli Lilly.
Qiagen gets FDA nod for colorectal cancer Dx
Qiagen is poised to cash in on the FDA's approval of Erbitux for colorectal cancer, as the agency also OK'd the Dutch firm's companion diagnostic for the top-selling cancer drug.
